Asia Pacific Clinical Trial Imaging Market Size, Share & Trends Analysis Report By Product and Services (Services, Software), By Application (Oncology, Neurology, Endocrinology, Cardiology, Dermatology, Haematology), By Modality (Computed Tomography, Magnetic Resonance Imaging, Echocardiography, Nuclear Medicine, Positron Emission Tomography, X-Ray, Ultrasound, Optical Coherence Tomography, Others), By End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic and Government Research Institutes, Medical Device Manufacturers, Others) and By Country(China, Korea, Japan, India, Australia, Taiwan, South East Asia, Rest of Asia-Pacific) Forecasts, 2022-2030

Market Overview

The Asia Pacific region is expected to reach USD 411 million by 2030 with a CAGR of 5.7%. We are living in an era of rapid advancement in our understanding of human disease. However, the application of this knowledge in clinical settings has not kept up with the pace of discovery. The process of developing new drugs involves a number of steps, one of which is the conduct of clinical trials. A clinical trial imaging (CTI) study is a research study in which participants participate voluntarily. Each study examines a unique scientific question concerning the usefulness of imaging technologies in detecting illness, diagnosing it, guiding treatment, or monitoring its progress. Imaging techniques for clinical trials can be broken down into the following categories: In general, screening imaging clinical trials ask questions to help researchers determine which type of imaging test will detect disease early, possibly before symptoms appear.

Clinical trials involving diagnostic imaging investigate which types of imaging tests are most likely to effectively detect disease when only a suspicion of disease exists, which types of imaging tests can assist in monitoring a known condition, and which types of imaging tests can monitor the effectiveness of a therapy to determine whether or not it is working. Image-guided interventional clinical trials are designed to evaluate the efficacy of interventions that are guided by imaging.

Imaging techniques are becoming increasingly important in the provision of evidence for decision making in oncological clinical trials. Imaging is still used to define key study end points, even though conventional morphological imaging techniques and standardised response criteria that are based on tumour size measurements have been implemented.

Market Dynamics

• It would appear that the Asian continent is becoming an increasingly popular location for conducting clinical trials that are efficient with regard to cost and make use of the available pool of treatment-naive subjects. This drives the growth of clinical trials imaging in Asia.
• Trial costs for data management, biostatistics, and laboratory testing, including bioanalytics are very low compared to US and Europe in Asia pacific. That is the reason it has become hot spot for clinical trials. The subjects for clinical trials are easily available in Asia.
• Rapidly increasing population in countries like China & India, increasing need of R&D and improved therapies are also driving the market growth in this region.

Asia Pacific Clinical Trial Imaging Market Restraints

• Diverse region & culture of Asia Pacific

Different countries have different regulatory requirements and processes, so sponsors who want to use the APAC region for their global clinical trials may have to learn the local rules in each country and choose local research sites that are familiar with and can follow ICH-GCP guidelines. Furthermore, the standard of care may differ from country to country, influencing recruitment rates and overall clinical trial timelines.

Sponsors should also consider the APAC region's ethnic, cultural, and linguistic diversity. The ways in which people of different ethnicities and cultures understand disease and their perspectives on taking part in clinical trials are influenced by these factors. In addition, this diversity can contribute to the complexity of the study, as it may necessitate the translation of study materials as well as the training of site staff in multiple languages.

Regional Analysis

Asia pacific is divided further into these countries China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, and Rest of Asia-Pacific. The clinical trials in China, India & South Korea has been increasing because of the relatively lower cost and availability of the individuals needed to perform the trial. So far, all the regions of Asia have become a hot spot for clinical trials. Conducting trials in Australia has additional advantages, such as an efficient and pragmatic regulatory pathway, tax incentives for conducting trials within the country, and the ability to conduct early phase trials prior to IND submission.

Segmental Analysis

The Asia Pacific clinical trial imaging market is divided into services and software based on product and service. It is divided into modality segments such as computed tomography, magnetic resonance imaging, echocardiography, nuclear medicine, positron emission tomography, X-ray, ultrasound, optical coherence tomography, and others. Further, it is divided into oncology, neurology, endocrinology, cardiology, dermatology, haematology, and others on the basis of application. Further division is on the basis of end users into pharmaceutical and biotechnology companies, contract research organisations, academic and government research institutes, medical device manufacturers, and others.

Impact of covid-19

COVID Impact: During COVID-19, supply chain interruptions hampered the trade, causing a lack of raw materials for producers and a delay in delivering finished items in the form of blind bolts to customers. As official prohibitions around the world have been lifted, demand for blind bolts has already begun to rebound to pre-pandemic levels.

Recent Developments

• March 2022, OCE+ is the first of several new enhancements to IQVIATM's leading life science customer engagement platform. OCE+ incorporates IQVIA's Next Best recommendation engine – a daily workflow tool that provides AI-driven recommendations for engaging healthcare professionals (HCP) – into its Orchestrated Customer Engagement (OCE) platform, resulting in improved HCP experiences, increased productivity, and ROI.
• February 2022, A partnership between Parexel and the n-Lorem Foundation will support the development of new investigational therapies for patients with nano-rare diseases.
• May 2022, Thermo Fisher Scientific's PPD clinical research business has been recognised for excellence in the 2022 CRO Leadership Awards. This is the eleventh year in a row that the company has been recognised by this award programme. The programme is founded on the responses of pharmaceutical and biotech industry professionals to a survey that was carried out by Clinical Leader magazine and Life Science Leader magazine.